Literature DB >> 21153673

Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients.

Maria José Santos1, Diana Fernandes, Susana Capela, Jose Canas da Silva, João Eurico Fonseca.   

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine with an important pathophysiological role in systemic lupus erythematosus (SLE). The polymorphism of the IL-6 gene promoter at position -174, which appears to influence the production of this cytokine, has been associated with susceptibility to some rheumatic diseases. The aim of this study is to investigate whether the IL-6 -174 G/C polymorphism associates with lupus susceptibility or affects disease characteristics in Portuguese patients with SLE. The association between -174 G/C and lupus diagnosis was studied in 115 adult SLE patients (95.7% females) and 152 healthy controls (94.7% females), all Caucasians. There were no significant differences in genotype or allele frequency between patients and controls. The -174 C/C genotype was independently associated with renal disease and the C allele with the presence of irreversible damage. The IL-6 gene promoter polymorphism at position -174 does not contribute to SLE susceptibility in Portuguese Caucasian patients but may predispose to specific manifestations of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153673     DOI: 10.1007/s10067-010-1640-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation.

Authors:  C F Terry; V Loukaci; F R Green
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

4.  Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein.

Authors:  Mark A Vickers; Fiona R Green; Catherine Terry; Bongani M Mayosi; Cecile Julier; Mark Lathrop; Peter J Ratcliffe; Hugh C Watkins; Bernard Keavney
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

5.  Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the rotterdam study and a meta-analysis.

Authors:  Mark P S Sie; Fakhredin A Sayed-Tabatabaei; Hok-Hay S Oei; André G Uitterlinden; Hubert A P Pols; Albert Hofman; Cornelia M van Duijn; Jacqueline C M Witteman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-11-03       Impact factor: 8.311

6.  Interleukin-6 promoter polymorphisms (-174 G/C) in Malaysian patients with systemic lupus erythematosus.

Authors:  K H Chua; B P Kee; S Y Tan; L H Lian
Journal:  Braz J Med Biol Res       Date:  2009-06       Impact factor: 2.590

7.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 8.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

9.  Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.

Authors:  Hye-Young Chun; Jae-Wook Chung; Hyoun-Ah Kim; Jeong-Moon Yun; Ja-Young Jeon; Young-Min Ye; Seung-Hyun Kim; Hae-Sim Park; Chang-Hee Suh
Journal:  J Clin Immunol       Date:  2007-06-21       Impact factor: 8.317

10.  Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus.

Authors:  Susana Mellor-Pita; Maria J Citores; Raquel Castejon; Miguel Yebra-Bango; Pablo Tutor-Ureta; Silvia Rosado; Jose L Andreu; Juan A Vargas
Journal:  Cytometry B Clin Cytom       Date:  2009-07       Impact factor: 3.058

View more
  10 in total

1.  Targeting IL-6 promoter polymorphism -174G/C should be dependent on ethnicity.

Authors:  Wang-Dong Xu; Yu-Jing Zhang; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2011-10-05       Impact factor: 2.980

Review 2.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

3.  Association of interleukin-6 promoter polymorphism (-174 G/C) with systemic lupus erythematosus.

Authors:  Ruo-Jie Li; Hai-Feng Pan; Chao Wang; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2011-04-01       Impact factor: 2.980

Review 4.  A meta-analysis of the association of IL-6 -174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk.

Authors:  Zaixing Yang; Yan Liang; Baodong Qin; Renqian Zhong
Journal:  Rheumatol Int       Date:  2013-09-07       Impact factor: 2.631

5.  Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus.

Authors:  Lijun Song; Feng Qiu; Yuchen Fan; Feng Ding; Huaxiang Liu; Qiang Shu; Weiwei Liu; Xingfu Li
Journal:  J Clin Immunol       Date:  2012-09-09       Impact factor: 8.317

6.  TGF-β1 limits the onset of innate lung inflammation by promoting mast cell-derived IL-6.

Authors:  Kirthana Ganeshan; Laura K Johnston; Paul J Bryce
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

Review 7.  Genetic risk factors of systemic lupus erythematosus in the Malaysian population: a minireview.

Authors:  Hwa Chia Chai; Maude Elvira Phipps; Kek Heng Chua
Journal:  Clin Dev Immunol       Date:  2011-09-20

8.  Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis.

Authors:  Karin Bolin; Johanna K Sandling; Agneta Zickert; Andreas Jönsen; Christopher Sjöwall; Elisabet Svenungsson; Anders A Bengtsson; Maija-Leena Eloranta; Lars Rönnblom; Ann-Christine Syvänen; Iva Gunnarsson; Gunnel Nordmark
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

Review 9.  Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update.

Authors:  Hua Su; Chun-Tao Lei; Chun Zhang
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

10.  Role of the promoter polymorphism IL-6 -174G/C in dermatomyositis and systemic lupus erythematosus.

Authors:  Maria Hristova; Lyubomir Dourmishev; Zornitsa Kamenarska; Svetla Nikolova; Radka Kaneva; Anton Vinkov; Marta Baleva; Daniela Monova; Vanio Mitev
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.